FDA approves first postpartum depression drug

Remaining Ad Time Ad - 00:00

LA CROSSE, Wis. (WXOW) – For the first time the U.S. Food and Drug Administration has approved a drug made specifically for the treatment of postpartum depression.

The intravenous drug will be sold as Zulresso and is shown to work almost immediately to treat the symptoms of postpartum. It will be administered as a single 60-hour IV drip and could cost between $20,000 and $30,000 dollars per treatment.

Dr. Heather Riese is an OBGYN at Gundersen Health System. She has high hopes for the new drug. She says, “It is bringing coverage and it is highlighting awareness of this horrible thing that affects women and can really affect both mom, baby and the rest of her family. I think the biggest impact that this drug is going to have is increasing awareness and recognition and getting more moms help.”

Postpartum depression is a serious mental illness that impacts 1-in-9 new mothers and can have life threatening consequences. The drug will be available to the public in June 2019.

 

Dani Smith

Dani Smith

News Producer

More News

STORMTRACKER 19 WEATHER

La Crosse
38°
Winona
36°
Decorah
Whitehall
35°
Prairie Du Chien
38°
Tomah
35°
Rochester
32°
Connect with WXOW

Top Stories

Scroll to top
Skip to content